TW200733961A - Diaryl urea for treating pulmonary hypertension - Google Patents

Diaryl urea for treating pulmonary hypertension

Info

Publication number
TW200733961A
TW200733961A TW095141431A TW95141431A TW200733961A TW 200733961 A TW200733961 A TW 200733961A TW 095141431 A TW095141431 A TW 095141431A TW 95141431 A TW95141431 A TW 95141431A TW 200733961 A TW200733961 A TW 200733961A
Authority
TW
Taiwan
Prior art keywords
pulmonary hypertension
treating pulmonary
diaryl urea
treating
diaryl
Prior art date
Application number
TW095141431A
Other languages
English (en)
Chinese (zh)
Inventor
Peter Sandner
Hanna Tinel
Joachim Huetter
Bernd Riedl
Martina Klein
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of TW200733961A publication Critical patent/TW200733961A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095141431A 2005-11-10 2006-11-09 Diaryl urea for treating pulmonary hypertension TW200733961A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
TW200733961A true TW200733961A (en) 2007-09-16

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095141431A TW200733961A (en) 2005-11-10 2006-11-09 Diaryl urea for treating pulmonary hypertension

Country Status (18)

Country Link
US (1) US20100035888A1 (enExample)
EP (1) EP1948170A1 (enExample)
JP (1) JP5084736B2 (enExample)
KR (1) KR20080067000A (enExample)
AR (1) AR057849A1 (enExample)
AU (1) AU2006312714A1 (enExample)
BR (1) BRPI0618522A2 (enExample)
CA (1) CA2628849A1 (enExample)
CR (1) CR9953A (enExample)
EC (1) ECSP088430A (enExample)
GT (1) GT200800058A (enExample)
IL (1) IL191178A0 (enExample)
NO (1) NO20082498L (enExample)
PE (1) PE20070806A1 (enExample)
SV (1) SV2009002900A (enExample)
TW (1) TW200733961A (enExample)
UY (1) UY29903A1 (enExample)
WO (1) WO2007054216A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
NZ577553A (en) * 2003-02-21 2011-01-28 Resmed Ltd Nasal assembly
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
PL1797038T3 (pl) * 2004-09-29 2012-11-30 Bayer Healthcare Llc Termodynamicznie trwała postać tosylanu bay 43-9006
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2675980C (en) * 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
EP2296641A1 (en) * 2008-06-25 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
WO2011130728A1 (en) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
AU2011310532B2 (en) 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
US20140127295A1 (en) * 2011-03-14 2014-05-08 Cellworks Group, Inc Compositions, process of preparation of said compositions and method of treating inflammatory diseases
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007832A (es) * 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003084543A1 (en) * 2002-04-10 2003-10-16 Virginia Commonwealth University Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr) * 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier

Also Published As

Publication number Publication date
ECSP088430A (es) 2008-07-30
AR057849A1 (es) 2007-12-19
KR20080067000A (ko) 2008-07-17
UY29903A1 (es) 2007-06-29
IL191178A0 (en) 2009-08-03
CR9953A (es) 2008-10-08
JP5084736B2 (ja) 2012-11-28
SV2009002900A (es) 2009-04-28
EP1948170A1 (en) 2008-07-30
JP2009514910A (ja) 2009-04-09
NO20082498L (no) 2008-08-07
CA2628849A1 (en) 2007-05-18
BRPI0618522A2 (pt) 2011-09-06
WO2007054216A1 (en) 2007-05-18
AU2006312714A1 (en) 2007-05-18
US20100035888A1 (en) 2010-02-11
PE20070806A1 (es) 2007-09-29
GT200800058A (es) 2010-02-23

Similar Documents

Publication Publication Date Title
TW200733961A (en) Diaryl urea for treating pulmonary hypertension
TW200735869A (en) Diaryl ureas for treating pulmonary hypertension
MX2007002397A (es) Nuevas composiciones farmaceuticas que comprenden acido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi) -piridina-2-carboxilico para el tratamiento de desordenes hiper-proliferativos.
TW200722100A (en) A therapeutic agent for a β related disorders
EA200702198A1 (ru) Фармацевтические составы
MX2009006055A (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxam il)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoi co.
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
ATE537828T1 (de) Psychotropes mittel und nahrungsmittel zur förderung der gesundheit enthaltend neferin
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
DE60221510D1 (de) Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
MX2010001243A (es) Composicion anti-inflamatoria.
WO2010123956A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
BRPI0514269A (pt) compostos heterocìclicos como agentes farmacêuticos
PL1979521T3 (pl) Nowy sposób impregnowania powierzchni tekstylnych
MX2010014441A (es) Diaril ureas para tratar la insuficiencia cardiaca.
ATE469635T1 (de) Haarbehandlungszusammensetzungen
UA91385C2 (ru) Диарилмочевина для лечения легочной гипертензии
WO2007054303A3 (en) Diaryl urea for treating diabetic neuropathy
FR2911278B1 (fr) Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant
WO2007027519A3 (en) Compositions and methods for darkening keratinous fibers
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
WO2007002093A3 (en) Ansamycin formulations and methods of use thereof
WO2004006900A3 (en) Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases
UA94598C2 (ru) Диарилмочевины для лечения легочной гипертензии